140 related articles for article (PubMed ID: 20113982)
1. Adherence to cervical screening in the era of human papillomavirus vaccination: how low is too low?
Bauch CT; Li M; Chapman G; Galvani AP
Lancet Infect Dis; 2010 Feb; 10(2):133-7. PubMed ID: 20113982
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of the quadrivalent human papillomavirus vaccine against cervical dysplasia in Manitoba, Canada.
Mahmud SM; Kliewer EV; Lambert P; Bozat-Emre S; Demers AA
J Clin Oncol; 2014 Feb; 32(5):438-43. PubMed ID: 24395857
[TBL] [Abstract][Full Text] [Related]
3. [Human papillomavirus (HPV) vaccines--a new method for the prevention of cervical cancer].
Friedek DA; Ekiel AM; Martirosian G
Wiad Lek; 2007; 60(1-2):34-8. PubMed ID: 17607966
[TBL] [Abstract][Full Text] [Related]
4. Cytology and cervical cancer surveillance in an era of human papillomavirus vaccination.
Budd AC; Sturrock CJ
Sex Health; 2010 Sep; 7(3):328-34. PubMed ID: 20719223
[TBL] [Abstract][Full Text] [Related]
5. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women.
Muñoz N; Kjaer SK; Sigurdsson K; Iversen OE; Hernandez-Avila M; Wheeler CM; Perez G; Brown DR; Koutsky LA; Tay EH; Garcia PJ; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Steben M; Bosch FX; Dillner J; Huh WK; Joura EA; Kurman RJ; Majewski S; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan JT; Lupinacci LC; Giacoletti KE; Sings HL; James MK; Hesley TM; Barr E; Haupt RM
J Natl Cancer Inst; 2010 Mar; 102(5):325-39. PubMed ID: 20139221
[TBL] [Abstract][Full Text] [Related]
6. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
7. Assessing the epidemiological impact on cervical cancer of switching from 4-valent to 9-valent HPV vaccine within a gender-neutral vaccination programme in Switzerland.
Kind AB; Pavelyev A; Kothari S; El Mouaddin N; Schmidt A; Morais E; Guggisberg P; Lienert F
BMC Public Health; 2020 May; 20(1):671. PubMed ID: 32398057
[TBL] [Abstract][Full Text] [Related]
8. Impact of human papillomavirus vaccination on rates of abnormal cervical cytology and histology in young New Zealand women.
Innes CR; Williman JA; Simcock BJ; Hider P; Sage M; Dempster-Rivett K; Lawton BA; Sykes PH
N Z Med J; 2020 Jan; 133(1508):72-84. PubMed ID: 31945044
[TBL] [Abstract][Full Text] [Related]
9. What's next? Perspectives and future needs of cervical screening in Europe in the era of molecular testing and vaccination.
Lynge E; Antilla A; Arbyn M; Segnan N; Ronco G
Eur J Cancer; 2009 Oct; 45(15):2714-21. PubMed ID: 19695870
[TBL] [Abstract][Full Text] [Related]
10. Impact of human papillomavirus (HPV) 16 and 18 vaccination on prevalent infections and rates of cervical lesions after excisional treatment.
Hildesheim A; Gonzalez P; Kreimer AR; Wacholder S; Schussler J; Rodriguez AC; Porras C; Schiffman M; Sidawy M; Schiller JT; Lowy DR; Herrero R;
Am J Obstet Gynecol; 2016 Aug; 215(2):212.e1-212.e15. PubMed ID: 26892991
[TBL] [Abstract][Full Text] [Related]
11. Predicted impact of vaccination against human papillomavirus 16/18 on cancer incidence and cervical abnormalities in women aged 20-29 in the UK.
Cuzick J; Castañón A; Sasieni P
Br J Cancer; 2010 Mar; 102(5):933-9. PubMed ID: 20104226
[TBL] [Abstract][Full Text] [Related]
12. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs.
Kulasingam SL; Myers ER
JAMA; 2003 Aug; 290(6):781-9. PubMed ID: 12915431
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of human papillomavirus vaccination and screening in Spain.
Diaz M; de Sanjose S; Ortendahl J; O'Shea M; Goldie SJ; Bosch FX; Kim JJ
Eur J Cancer; 2010 Nov; 46(16):2973-85. PubMed ID: 20638840
[TBL] [Abstract][Full Text] [Related]
14. Advances in cervical cancer screening and human papillomavirus vaccines.
Feeley C
J Br Menopause Soc; 2006 Mar; 12(1):19-23. PubMed ID: 16513018
[TBL] [Abstract][Full Text] [Related]
15. The efficacy of HPV 16/18 vaccines on sexually active 18-23 year old women and the impact of HPV vaccination on organized cervical cancer screening.
Sigurdsson K; Sigvaldason H; Gudmundsdottir T; Sigurdsson R; Briem H
Acta Obstet Gynecol Scand; 2009; 88(1):27-35. PubMed ID: 19031282
[TBL] [Abstract][Full Text] [Related]
16. Estimation of the potential overall impact of human papillomavirus vaccination on cervical cancer cases and deaths.
Van Kriekinge G; Castellsagué X; Cibula D; Demarteau N
Vaccine; 2014 Feb; 32(6):733-9. PubMed ID: 24291200
[TBL] [Abstract][Full Text] [Related]
17. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.
Arbyn M; Xu L; Simoens C; Martin-Hirsch PP
Cochrane Database Syst Rev; 2018 May; 5(5):CD009069. PubMed ID: 29740819
[TBL] [Abstract][Full Text] [Related]
18. Pap test update.
Heley S
Aust Fam Physician; 2007 Mar; 36(3):112-5. PubMed ID: 17339970
[TBL] [Abstract][Full Text] [Related]
19. Estimating the number needed to vaccinate to prevent diseases and death related to human papillomavirus infection.
Brisson M; Van de Velde N; De Wals P; Boily MC
CMAJ; 2007 Aug; 177(5):464-8. PubMed ID: 17709404
[TBL] [Abstract][Full Text] [Related]
20. The impact of bivalent HPV vaccine on cervical intraepithelial neoplasia by deprivation in Scotland: reducing the gap.
Cameron RL; Kavanagh K; Cameron Watt D; Robertson C; Cuschieri K; Ahmed S; Pollock KG
J Epidemiol Community Health; 2017 Oct; 71(10):954-960. PubMed ID: 28756395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
